#1 Clinical Trials Search in Europe
EU – Europe
AT – Austria
HR – Croatia
CZ – Czech Republic
DK – Denmark
EE – Estonia
FI – Finland
FR – France
DE – Germany
IS – Iceland
IT – Italy
LV – Latvia
LT – Lithuania
NL – Netherlands
NO – Norway
PL – Poland
PT – Portugal
RO – Romania
SK – Slovakia
SI – Slovenia
ES – Spain
SE – Sweden
  • Find a Clinical Trial

    Search Trials by Disease

    Non-small cell lung cancer Breast cancer Plasma cell myeloma Neoplasm Acute myeloid leukaemia Neoplasm malignant Colitis ulcerative Obesity Colorectal cancer metastatic Prostate cancer Crohn's disease Colorectal cancer Ovarian cancer Hepatocellular carcinoma Dementia Alzheimer's type Asthma Dermatitis atopic Breast cancer metastatic Non-small cell lung cancer metastatic Malignant melanoma More trials…
  • Rare Diseases Treatments

    Search Trials by Disease

    Craniocerebral injury Small cell lung cancer limited stage Graft versus host disease Cholangitis sclerosing Adenomatous polyposis coli Hepatic angiosarcoma Chronic lymphocytic leukaemia recurrent Glioblastoma Chronic lymphocytic leukaemia refractory Pelizaeus-Merzbacher disease Peripheral T-cell lymphoma unspecified Mycobacterium abscessus infection Bone marrow disorder Ventricular fibrillation Small intestine adenocarcinoma More trials…

    Learn about Rare Diseases

    Idiopathic pulmonary fibrosis – Basic Information Progressive supranuclear palsy Undifferentiated sarcoma – Basic Information Glycogen storage disease type II – Basic Information Langerhans cell sarcoma – Life with Disease Skin angiosarcoma – Treatment Cerebral arteriovenous malformation haemorrhagic VEXAS syndrome – Treatment Amyotrophic lateral sclerosis Hairy cell leukaemia More diseases
  • Vaccine Clinical Trials
  • Pediatric Clinical Trials
  • Resources for Patients

    Browse Innovative Treatments

    Pehero Romiplostim Asparaginase Ulotaront Sabatolimab Yttrium-90 Bay 3018250 LY3537021 Zofenopril Calcium Gskvx000000008866 Itolizumab Somatostatin Dordaviprone [18F]CPFPX Vx-264 FG001 Sulfonamides, Urea Derivatives Eptinezumab SELTOREXANT E.coli Polysaccharide More therapies…

    Learn about Your Condition

    Insulin resistance Marginal zone lymphoma Cardiac valve disease Amyloidosis Thymoma malignant Adrenal insufficiency Genital infection female Haemorrhage Coronary artery bypass Anal fistula Neonatal anoxia Pterygium Anal cancer metastatic Pulmonary alveolar haemorrhage Biliary neoplasm More diseases
  • Healthy Volunteers
  • Patient Guide
  • Our Partners
  • About Us
  • Contact us
  • Region
    🇪🇺 Europe
    🇦🇹 Austria
    🇭🇷 Croatia
    🇨🇿 Czech Republic
    🇩🇰 Denmark
    🇪🇪 Estonia
    🇫🇮 Finland
    🇫🇷 France
    🇩🇪 Germany
    🇮🇸 Iceland
    🇮🇹 Italy
    🇱🇻 Latvia
    🇱🇹 Lithuania
    🇳🇱 Netherlands
    🇳🇴 Norway
    🇵🇱 Poland
    🇵🇹 Portugal
    🇷🇴 Romania
    🇸🇰 Slovakia
    🇸🇮 Slovenia
    🇪🇸 Spain
    🇸🇪 Sweden

Von Willebrand’s disease

  • A Study of VGA039 to Prevent Bleeding in Teenagers and Adults with von Willebrand Disease Who Have Not Used Regular Preventive Treatment Before

    Recruiting

    3 1 1
    Investigated Drugs:
    • VGA039
    Austria Finland Germany Ireland Italy

  • Study on the Safety and Effectiveness of Emicizumab for Patients with Type 3 Von Willebrand Disease

    Recruiting

    3 1 1 1
    Investigated Diseases:
    • Von Willebrand’s disease
    Investigated Drugs:
    • Efmoroctocog Alfa
    • Factor Viii Inhibitor Bypassing Fraction
    • Human Coagulation Factor Viii
    Belgium France Germany Italy The Netherlands Poland +2

  • Study on the Effects of BT200 (Rondaptivon Pegol) for Patients with Type 2B von Willebrand Disease

    Recruiting

    2 1
    Investigated Diseases:
    • Von Willebrand’s disease
    Investigated Drugs:
    • Rondaptivon Pegol
    Austria

  • Study on Preventing Bleeding in Children with Severe von Willebrand Disease Using Vonicog Alfa and Octocog Alfa

    Recruiting

    3 1 1 1
    Investigated Diseases:
    • Von Willebrand’s disease
    Investigated Drugs:
    • Octocog Alfa
    • Vonicog Alfa
    France Ireland Italy Spain

  • Phase 2 Study of ALN-6400 Safety and Tolerability in Female Patients with Von Willebrand Disease and Heavy Menstrual Bleeding

    Not yet recruiting

    2 1 1
    Investigated Diseases:
    • Von Willebrand’s disease
    Investigated Drugs:
    • RNA, (UM-SP-(2′-DEOXY-2′-FLUORO)A-SP-GM-AM-AM-(2′-DEOXY-2′-FLUORO)A-CM-UM-CM-AM-UM-AM-GM-(2′-DEOXY-2′-FLUORO)C-GM-(2′-DEOXY-2′-FLUORO)A-UM-UM-GM-CM-AM-SP-CM-SP-AM), COMPLEX WITH RNA (UM-SP-GM-SP-CM-AM-AM-UM-(2′-DEOXY-2′-FLUORO)C-GM-(2′-DEOXY-2′-FLUORO)C-(2′-DEOXY-2′-FLUORO)U-(2′-DEOXY-2′-FLUORO)A-UM-GM-AM-GM-UM-UM-UM-CM-UM-AM) 3′-[[(2S,4R)-1-[29-[[2-(ACETYLAMINO)-2-DEOXY-Β-D-GALACTOPYRANOSYL]OXY]-14,14-BIS[[3-[[3-[[5-[[2-(ACETYLAMINO)-2-DEOXY-Β-D-GALACTOPYRANOSYL]OXY]-1-OXOPENTYL]AMINO]PROPYL]AMINO]-3-OXOPROPOXY]METHYL]-1,12,19,25-TETRAOXO-16-OXA-13,20,24-TRIAZANONACOS-1-YL]-4-HYDROXY-2-PYRROLIDINYL]METHYL HYDROGEN PHOSPHATE] (1:1)
    Germany The Netherlands Sweden

  • Study on the Effectiveness and Safety of Vonicog Alfa with or without Octocog Alfa for Children with Severe von Willebrand Disease Experiencing Bleeding or Undergoing Surgery

    Not recruiting

    3 1 1 1
    Investigated Diseases:
    • Von Willebrand’s disease
    Investigated Drugs:
    • Octocog Alfa
    • Vonicog Alfa
    Austria Belgium France Italy Spain

Investigational Drugs in This Location

See which drug candidates are part of clinical trials near you. Click for detailed trial information.

Medical Conditions Being Studied in This Location

Explore diseases currently included in clinical trials near you. Click to view trials and details for each condition.

European Clinical Trials Information Network

The European Clinical Trials Information Network is transforming access to clinical trial information for patients across Europe. By overcoming language barriers, our platform allows everyone, regardless of their native language, to easily find relevant and comprehensible clinical trial data. This innovative service connects patients to cutting-edge treatments, creating a unified European community where health and progress transcend borders.

This service is not affiliated with the European Commission, the EMA, or the official CTIS system. Most information comes from publicly available international clinical-trial registries, supplemented by data from academic centres, national regulators, and commercial sponsors. We aim to keep all content accurate and up to date.

Explore the full ecosystem of clinical research in Europe.

The information provided on this website is mainly derived from international public clinical trial databases (CTIS.eu). In addition, we are including supplementary sources, such as information provided by academic centers and national regulators, as well as information supplied by commercial sponsors (pharmaceutical companies and contract research organizations). We try to ensure that the information provided is accurate and up to date.

Certain content and visual elements on this website have been generated or enhanced using artificial intelligence (AI).

The website is published by:
CTIN POLAND sp. z o.o.
with its registered office in Warsaw,
ul. rtm. Witolda Pileckiego 67/109,
02-781 Warsaw, Poland,
entered in the Register of Entrepreneurs of the National Court Register under KRS number 0001111334,
REGON: 528919042, NIP (Tax ID): 9512598637
Contact us

© 2026 CTIN Poland

Privacy Policy

Terms and Conditions

Contact

For Sites and Sponsors

Clinical Trial Locations

We use cookies

The website uses cookies to ensure the proper functioning of the site and to analyze internet traffic. Some cookies are essential for using the service and do not require consent. You can accept all cookies or use only the essential ones. Data is processed in accordance with our Privacy Policy. You have the right to withdraw your consent, access, rectify, delete, or limit the processing of your data at any time.
Numer nieprawidłowy!
Numer nieprawidłowy!